Skip to search formSkip to main contentSkip to account menu

TAS-115

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 2141: TAS-115, a novel and highly potent VEGFR/MET inhibitor, shows prominent antitumor efficacy by restoring HGF-mediated hypoxia-resistant phenotype in clear cell sarcoma
Hepatocyte growth factor (HGF) / HGF receptor (MET) signaling is considered to be involved in chemoresistance to cancer treatment… 
2014
2014
The novel VEGF receptor/MET-targeted kinase inhibitor, TAS-115, has marked in vivo anti-tumor properties and a favorable tolerability profile
2012
2012
Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL MET is known as a proto-oncogene, which involves… 
2011
2011
Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
c-Met is a receptor tyrosine kinase involved in various malignant phenotypes of diverse cancers. The inhibition of VEGF/VEGFR has… 
2011
2011
Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL c-Met is a multi-functional proto-oncogenic receptor…